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PERSPECTIVES_IN CLINICAL NEPHROLOGY
Hepatitis C virus infection in dialysis and renal transplantation
Liver disease is an important cause of morbidity and mortality
in patients with chronic renal failure treated by dialysis and
transplantation [1—101. Elevated serum alanine aminotransferase
(ALT) levels are seen in 10 to 44% of patients on chronic
hemodialysis and 7 to 24% of transplant recipients. Further, liver
failure is the cause of death in 8 to 28% of long-term survivors
after renal transplantation. In the past, approximately half of
these cases of liver disease were attributed to viral infections such
as hepatitis B virus (HBV), Epstein-Barr virus or cytomegalovirus,
drugs such as alcohol, azathioprine or cyclosporine, and hemo-
siderosis. The remaining cases were attributed to non-A, non-B
hepatitis (NANBH) [2—4, 8, 9, 111.
In 1989, the hepatitis C virus (HCV) was cloned and identified
as the major cause of parenterally transmitted NANBH [12, 13].
The transmission of HCV by transfusion of blood products and by
sharing of needles among intravenous drug abusers has been
unequivocally demonstrated [14—161. Horizontal transmission by
sexual and/or household exposure and vertical transmission from
mother to fetus have also been reported [17—26]. Tests are now
available that detect antibodies to multiple HCV antigens (anti-
HCV), and the presence and titer of HCV RNA [13, 27, 28].
These advances opened avenues to study the prevalence, trans-
mission and natural course of HCV infection in patients with
end-stage renal disease (ESRD).
Patients with ESRD are at risk of acquiring HCV infection
from blood product transfusions, organ donors or other patients
in hemodialysis (HD) units. The advent of screening of blood
products for anti-HCV has virtually eliminated the transmission
of HCV infection by blood product transfusions [29]. Conse-
quently, the current debate is focused on other strategies to
reduce the transmission of HCV infection among dialysis and
transplant patients and to lessen the consequences of liver disease
in patients already infected. Important questions include: (1) Do
infection control measures prevent nosocomial transmission of
HCV in dialysis units? (2) Can kidneys from anti-HCV positive
donors be transplanted safely? (3) What is the effect of renal
transplantation on the course of HCV infection in patients on
dialysis? and (4) When should interferon alpha (IFNa) be used in
the treatment of chronic HCV infection in dialysis and renal
transplant patients?
Answers to these questions are still evolving and there are no
widely agreed upon policies at the present time. The objectives of
this review are to discuss the background information that is
essential for evaluating treatment recommendations and dialysis
unit and transplant center policies. We review: (1) the structure of
HCV and tests to detect HCV infection; (2) features of HCV
infection; (3) prevalence of HCV infection and risk factors for
infection in dialysis patients; (4) nosocomial transmission in HD
units; (5) transmission by organ transplantation; (6) impact of
infection on clinical outcomes in renal transplant recipients; and
(7) efficacy, safety and timing of IFNa treatment of chronic HCV
infection in ESRD.
Hepatitis C virus and tests to detect infection
Structure of HCV genome
The hepatitis C virus is a small 40 to 60 nm virus with a lipid
envelope and a single-stranded RNA viral genome comprising
approximately 9,400 nucleotides [12, 30]. The virus has similar
genome organization and some sequence homology with the
human flaviviruses and animal pestiviruses, all of which are now
considered members of the Flaviviridae family [301. The N-
terminus encodes the basic nucleocapsid (C) followed by two
glycoprotein domains, the envelope (El) and second envelope/
non-structural-i (E2/NS 1) regions (Fig. 1) [301. Downstream to
this region are the non-structural genes NS2, NS3, NS4 and NS5,
respectively. Several HCV genotypes have been identified and
significant genetic heterogeneity has been observed over the
entire viral genome [18, 31, 321. The degree of variability between
different genotypes varies with the region of the viral genome.
Regions encoding the El and E2/NS1, are the most variable [33,
34]. The NS4 region is also highly variable, although some
immunogenic epitopes within this immunoreactive part of the
viral genome are well conserved [35, 36]. Likewise, the NS5 region
displays sufficient variability to allow for the identification of
different genotypes [32]. In contrast, the 5' non-coding region
(5'NCR) represents the most conserved sequence [37—40].
Sequence analysis of the viral genome has identified a number
of distinct HCV variants which has led to a variety of classification
systems (Table 1) [30, 41—48]. Recently, a universal system for the
nomenclature of hepatitis C viral genotypes has been proposed
[41]. Based on the data from an international collaborative study
[32], which compared the nucleotide sequences in the NS5 region
of a world-wide panel of HCV variants and other published
isolates, this consensus classification defined six major groups (#1
to #6), designated as HCV types [41]. Sequence homology
between different types ranges from 55% to 72% (mean 65%).
Each major type consists of one or more closely related variants,
designated as subtypes and named a, b, c, etc., in order of
discovery. The sequence homology between subtypes ranges from
75% to 86% (mean 80%). Finally, each subtype may consist of
individual isolates with sequence homology of around 88%.
Tests for HCV RNA
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Polymerase chain reaction. The detection of HCV RNA by
reverse transcriptase polymerase chain reaction (PCR) has been
used as the "gold standard" to identify current HCV infection [27,
49, 50]. Since the nucleotide sequence of the highly conserved 5'
end is shared by most HCV strains, "universal" primers directed
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to this region are used to identify the presence or absence of the
virus. In patients with post-transfusion NANBH, high levels of
HCV RNA are detected in the circulation within a week, prior to
the appearance of anti-HCV [14, 27]. Nonetheless, the reliability
of this test is limited by false positive and false negative results.
Busch and colleagues have shown that imperfect handling and/or
storage of blood samples can lead to failure to detect HCV RNA
in up to 40% of samples [51]. The extreme sensitivity of the PCR,
which can detect the presence of HCV RNA levels as low as 2000
copies/ml [52], is also its shortcoming and rigorous measures are
required to prevent false positive results due to even minor
contamination [53]. Finally, performance of PCR is labor inten-
sive, protocols vary from laboratory to laboratory, and the test is
available in only select laboratories [54]. At the present time, PCR
is not licenced for clinical use.
Quantitation of HCV RNA titers, The branched-chain DNA
assay (bDNA assay) is a quantitative assay for HCV RNA in
which the signal/probe rather than viral nucleic acid is amplified
[55, 56]. Specific probes to the 5' untranslated and core regions of
the HCV genome, "capture" and bind HCV RNA to a solid
phase. This signal is then amplified using synthetic amplification
multimers, followed by hybridization of enzyme labeled to the
amplification multimers. HCV RNA is quantified by addition of
dioxetane and comparing the chemilumiriescence in the test
sample to that from known standards of HCV RNA. The lower
limit of detection of the bDNA assay is 350,000 molecules/mI [56]
Fig. 1. Schematic representation of the hepatitis
C viius genome. Shaded boxes represent
antigens used in anti-HCV tests systems.
Abbreviations are: C, core; E, envelope; NS,
non-structural.
compared to 2000 molecules/mI for PCR [52]. Based on a positive
PCR, the sensitivity of this test is 72% [56]. Although the bDNA
assay is less sensitive than PCR, it is simple, automated, repro-
ducible and could exclude false positive results due to contami-
nation [56]. Conversely, bDNA negative, PCR positive patients
could have low circulating viral titers. In addition to the bDNA
assay, quantitative PCR has also been used to measure the level of
HCV RNA in serum [27].
Tests for genotypes. Precise identification of the specific viral
type, subtype or isolate requires sequence analysis of the viral
genome [17, 18, 57—60]. However, this procedure is expensive,
time-consuming and is fraught with the problem of mutations [61].
Consequently, PCR using subtype, specific primers have been
used to identify HCV subtypes [18]. After detection of HCV RNA
using PCR with primers directed to the 5' end, primers comple-
mentary to the core and NS5 regions that are specific to a
particular subtype are used to detect the presence of a particular
subtype. Hepatitis C virus genotypes have also been studied by
means of restriction fragment length polymorphism (RFLP)
analysis and line probe assay based on type-specific sequence
variations in the 5' untranslated region [61, 62]. Others have used
an enzyme-linked immunosorbent assay that detects antibodies to
serotype-specific immunodominant epitopes from the NS4 region
of the HCV genome [35, 63].
Tests for antibody to HCV
Because of technical difficulties in detecting HCV RNA, tests
for antibody to HCV (anti-HCV) are the mainstay of clinical
diagnosis of HCV infection. Enzyme-linked immunosorbent as-
says (ELISA) and recombinant immunoblot assays (RIBA) have
been used to detect non-neutralizing antibodies. ELISA detects
antibody to a specific HCV antigen (first generation tests) or a
combination of antigens (second and third generation tests) in a
standard ELISA plate. In contrast, the RIBA detects antibodies to
one or more HCV antigens on a strip that is read visually. While
ELISAs have been used as screening tests, RIBAs have been
considered confirmatory tests by virtue of their increased speci-
ficity. The first-generation anti-HCV tests (ELISA1, RIBAI)
detect a non-neutralizing antibody, directed to a recombinant
antigen (clOO) from the N54 region of the viral genome. The
mean interval from transfusion with HCV-infected blood prod-
ucts to seroconversion with the first generation tests was 16 weeks,
but could be as long as one year. Using these assays, anti-HCV
was ultimately detected in 46 to 89% of patients [16, 64]. The early
stage in HCV infection, when HCV RNA is present, but antibody
response is not yet manifest, is defined as the "window" period
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Table 1. Nomenclature of HCV genotypes [41]
NC is not classified. Reference numbers are in brackets.
Simmonds, Hepatology, 1994, by permission of W.B. Saunders Com-
pany.
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[14]. The limited sensitivity of first generation tests was due, in
part, to substantial sequence diversity of NS4 among the various
HCV genotypes [35]. The second generation tests have partly
abrogated this limitation by increasing the number of the incor-
porated antigens. ELISA2 incorporates c22 antigen from the
nucleocapsid region and c200, which is a composite of c33 and
clOO—3 antigens from the NS3/NS4 region. RIBA2 uses four
recombinant HCV antigens (c22, c33, c100, and 5-1-1). The use of
a recombinant protein from the putative nucleocapsid region of
the HCV genome could presumably reduce the window period
between infection and seroconversion, since the antibody re-
sponse against this capsid antigen occurs earlier than that against
other HCV antigens [65]. Indeed, second generation tests can
detect seroconversion as early as four weeks after exposure [64].
Recently, third generation anti-HCV tests have become available.
Both the ELISA3 and RIBA3 incorporate an additional recom-
binant antigen from the NS5 region, and the antigen correspond-
ing to the NS3 region (c33) has been improved. In theory, further
inclusion of antigens from regions of the HCV genome not
represented in the previous tests could further improve the
sensitivity.
In addition to the above, tests that detect specific antibodies
have been developed that could detect the early 1gM antibody
response to the NS3 region in patients exposed to HCV infection
[66]. Furthermore, the duration of HCV infection can potentially
be estimated by an IgG antibody avidity test [67]. Patients with
recent infection (within 50 days from seroconversion) have a low
avidity index as opposed to patients with long-term infection (at
least 300 days after seroconversion) who have a high avidity index.
Indeed, longitudinal follow-up of a cohort of patients with newly
acquired HCV infection revealed that the avidity index increased
significantly as time elapsed after primary infection. This antibody
test could also distinguish between primary antibody response and
passively acquired antibody [67].
Difficulties in inteipreting tests for HCV infection
Anti-HCVpositive, but I-ICVRNA negative patients. As discussed
above, the anti-HCV tests that are currently licenced for clinical
use detect non-neutralizing antibodies to recombinant HCV
antigens. Thus, the presence of anti-HCV does not necessarily
imply the presence of HCV RNA in the serum. However, Alter
and colleagues observed that serum HCV RNA was detectable in
100% of non-immunosuppressed individuals with post-transfusion
HCV infection [68]. Based on these findings, they and others have
suggested that serum HCV RNA is probably present in all
patients with HCV infection [68, 69]. This view is not shared by
others and numerous studies document the absence of HCV RNA
in patients with anti-HCV [14, 27, 49, 50, 70—72]. Indeed, HCV
RNA has been detected in only 37 to 73% blood donors, 72% of
intravenous drug abusers and hemophiliacs, 81 to 86% of patients
with chronic NANBH and 52 to 93% of dialysis patients with
anti-HCV [27, 49, 50, 70—72]. Several possibilities could account
for the presence of anti-HCV in the absence of HCV RNA. (1)
HCV may be sequestered at sites other than the blood stream
[71]. For instance, HCV may be localized exclusively to the liver
or peripheral blood mononuclear cells (PBMC) [73]. Indeed, the
viral genome is transcribed and replicates in these cells, and it can
be detected by PCR in these specimens [73]. (2) Viremia could be
intermittent and therefore, HCV RNA may not be present in the
plasma at the time of testing [i1. Indeed, patients with persistent
post-transfusion hepatitis C have been found to have fluctuating
blood levels of HCV RNA, and HCV RNA can transiently
disappear from the circulation. (3) The number of copies of HCV
RNA may be below the limit of detection [74]. (4) Antibody to
HCV may persist even after the viral RNA has disappeared. In
this situation, anti-HCV positive, but HCV RNA negative pa-
tients might represent a group that had been infected with the
virus, but no longer harbor it, and for this reason are no longer
infective. (5) Anti-HCV may have been passively acquired from
blood transfusions. In this situation, anti-HCV would disappear
over the next few weeks in keeping with the half-life of IgG.
However, if the recipient acquires the HCV infection, anti-HCV
would re-appear as soon as active antibody production begins
[151. (6) False positive results can occur due non-specific reac-
tions, a problem which has been largely resolved in the current
tests.
Anti -HC V negative, but HCV RNA positive patients. More than
90% of non-immunosuppressed individuals with HCV infection
test positive for anti-HCV [68]. Possible explanations for the
presence of HCV RNA in the absence of anti-HCV include: (1)
The anti-HCV test may not be sensitive enough to detect existing
anti-HCV antibody, either due to the low titer of antibody or
because the antigen used in the assay system cannot detect the
serum antibody response to the particular genotype [35, 68]. (2)
Various diseases or pharmacological immunosuppression could
suppress or modify the anti-HCV response [75]. Indeed, only 83%
of HCV RNA-positive dialysis patients test positive for anti-HCV,
and 2.5 to 12% of anti-HCV negative dialysis patients test positive
for HCV RNA [76—80]. Likewise, among HCV RNA positive
transplant recipients, anti-HCV was detected by ELISA1, ELISA2
and RIBA2 in 35%, 70% and 52%, respectively [81]. (3) The
patient may be in the "window" period between infection and
seroconversion. (4) After anti-HCV antibody has persisted for a
certain period of time, it can disappear despite the persistence of
HCV RNA [14]. In addition to the above, HCV RNA has been
detected in the PBMC from HD patients without anti-HCV or
HCV RNA in the serum [82]. The HCV RNA in these PBMC
could serve as a viral reservoir and further frustrate efforts to
identify HCV infection in HD patients.
Clinical features of HCV infection
Prevalence in healthy population
Hepatitis C is a worldwide infection. However, the prevalence
of anti-HCV in the general population varies widely among
different countries and geographic areas. Using first generation
tests, the prevalence of anti-HCV among blood donors ranges
from 0.5 to 11.4% in North America [83—861, 1.2% in South
America [87], 0 to 1.3% in Europe [19, 88—93], 0.3 to 1.3% in Asia
[94, p51, 2.2% in Africa [96], and 0.5% in New Zealand [97]. HCV
infection is apparently endemic in some regions of the world such
as Thailand, Vietnam, Camcroon and Egypt where prevalence as
high as 4 to 22% has been reported among traditional low-risk
groups such as blood donors, school children and army recruits
[98—101].
Clinical course of HCV infection
Among patients with post-transfusion hepatitis C, HCV RNA is
detected in the serum within one to three weeks after exposure
followed by elevated serum alanine aminotransferase levels
984 Pereira and Levey: Hepatitis C infrction
(ALT), several weeks later [14]. As discussed earlier, seroconver-
sion for anti-HCV begins at four weeks, but can take as long as
one year [16, 64]. The majority of non-immunosuppressed indi-
viduals ultimately develop antibody to multiple viral proteins, and
these antibodies persist over a long period of time [102—104].
Among patients with post-transfusion HCV infection, 50% have
self-limited disease and 50% have persistently elevated serum
alanine aminotransferase (ALT) levels. Of those who undergo
liver biopsy, 60% have chronic active hepatitis and 10 to 20%
cirrhosis [105]. Some of these patients progress to develop
hepatocellular carcinoma [106—108]. Seeff and colleagues have
recently reported the results of long-term follow-up from five
studies of transfusion-associated hepatitis that began between
1967 and 1980 [109]. After an average of 18 years, the overall
mortality was 51% in patients with post-transfusion NANBH and
in two control groups of patients who had received transfusions
but had not developed hepatitis. Among patients with post-
transfusion NANBH, the frequency of death due to liver disease
was also low (3.3%), but significantly higher than in the control
groups (1.1% and 2.0%). It is possible that longer follow-up may
be required to reveal a difference in the mortality between the
groups. This possibility is supported by Kiyosawa and colleagues
who have shown that in patients with post-transfusion NANBH,
the interval between the initial presentation and the onset of
chronic hepatitis, cirrhosis and hepatocellular carcinoma is 10, 21
and 29 years, respectively [106].
Relationship among serum alanine aminotransferase levels, HCV
infection and liver disease
In general, the greater the elevation in liver enzymes, the higher
is the probability of histological evidence of the liver disease in
HCV infection [110]. Nonetheless, the correlation is weak and
serum alanine aminotransferase (ALT) levels are poor predictors
of liver disease. Elevated ALT levels are detected in only 20% of
anti-HCV-positive blood products [liii and 33% of anti-HCV-
positive blood donors [112]. Among HD patients, serum ALT
levels are elevated in only 4 to 67% patients with anti-HCV, only
12 to 31% of patients with HCV RNA and only one third of those
with biopsy-proven hepatitis [72, 87, 104, 113—117]. Likewise,
biochemical evidence of liver disease is present in only 42 to 52%
of the HCV RNA positive transplant recipients [81, 118]. The
discrepancy between serum ALT levels and the presence of
anti-HCV is due to several reasons. (1) Chronic hepatitis C
characteristically has a fluctuating course with multiple peaks and
troughs in ALT levels [14], and patients with normal ALT levels
may have severe histological lesions. (2) HCV infection is not
always associated with chronic liver disease. In fact, only 69% of
ariti-HCV positive symptom-free blood donors who underwent
liver biopsy had histologic evidence of chronic hepatitis, all of
whom had HCV RNA in the serum [119]. Therefore, a healthy
carrier state can exist with viral replication occurring at extra-
hepatie sites. One possible explanation for this is that some
patients may be unable to mount a strong immune response to
HCV and thus to cause hepatic injury [74]. (3) As discussed
earlier, some anti-HCV-positive patients may have cleared the
infection and anti-HCV may he the remnant of past infection. (4)
Baseline ALT levels are depressed in patients on dialysis [120].
Interestingly, elevated ALT levels have also been observed in 4 to
23% of anti-HCV negative dialysis patients [72, 116, 117, 121,
122]. These patients could be carriers of HCV infection in whom
anti-HCV production is absent, or the liver disease might be due
to a non-A, non-B virus other than HCV, or to non-viral causes.
Consequently, liver biopsy remains the only reliable method of
confirming the presence and assessing the severity of liver disease
in patients with HCV infection. Indeed, liver histology at the time
of initial presentation has been shown to be a good predictor of
intermediate and long-term outcome in transplant recipients with
liver disease [11]. Over a mean follow-up of six years, progression
to liver failure and death was rare in transplant recipients with
mild histological abnormalities such as fat metamorphosis or
chronic persistent hepatitis [ii]. In contrast, 35% of recipients
with early chronic active hepatitis and 60% of recipients with
advanced chronic active hepatitis progressed to liver failure and
death [11].
Clinical importance of different HCV genotypes
The clinical significance of genomic diversity of HCV has yet to
be completely elucidated. Nonetheless, biological differences be-
tween viral genotypes may play an important role in the epidemi-
ology and natural history of HCV infection. Several reports have
emphasized genotype-related differences in disease severity, clin-
ical outcomes and response to interferon in patients with chronic
hepatitis C [123, 124]. In patients without renal failure, infection
with genotype lb has been associated with more severe liver
disease (cirrhosis and hepatocellular carcinoma), a greater cyto-
pathic effect in liver transplant recipients, and a lower rate of
response to interferon treatment [124, 125]. In contrast, Mahaney
and colleagues have observed that genotype 2 was associated with
more serious liver disease (chronic active hepatitis or cirrhosis),
despite significantly lower levels of circulating HCV RNA com-
pared to other genotypes [126]. Also, a long-term sustained
response to IFN-cs treatment occurred less frequently in patients
infected with genotype 1 (7%) than in patients with other
genotypes (40%) [126].
Immunity
As discussed earlier, humans exposed to HCV develop chronic
infection despite the presence of antibodies to multiple regions of
the HCV genome. The majority of these antibodies are non-
neutralizing and hence do not represent immunity. Although
neutralizing antibodies to the envelope regions of HCV have
recently been characterized, their role in protective immunity has
not been demonstrated [127]. Indeed, studies in humans and
animals with HCV infection have revealed lack of protective
immunity against reinfection (new infection after the previous
infection has cleared) with the same or different genotype [60,
128] or superinfection (infection with a new genotype in presence
of pre-existing infection) [129]. Reinfection has been reported in
thalassemic children after multiple blood transfusions [128]. In
one case, superinfection with genotype 2a was observed in a
patient with HCV infection with type lb [129]. Early in the course,
both genotypes were detected, but later in the course, genotype 2a
disappeared and only lb was detectable. In chimpanzees with
convalescent HCV infection, Farci and colleagues have demon-
strated that rechallenge with the same or different HCV genotype
consistently resulted in the recurrence of viremia and biochemical
and histological evidence of hepatitis [60]. However, in chimpan-
zees with persistent HCV infection, rechallenge with a different
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HCV genotype failed to induce superinfection. In contrast, Oka-
moto and colleagues could induce superinfection with HCV of
genotype la in two chimpanzees with persistent HCV infection
with genotype lb [1301. While genotype lb was undetectable 22
weeks after the challenge and thereafter, genotype la persisted
and was believed to "take over" the infection. However, challenge
with HCV genotype 2a resulted in hepatitis flare, but failed to
induce superinfection as judged by the absence of HCV RNA of
this genotype in the chimpanzees' sera. Overall, these reports
indicate that HCV infection does not induce protective immunity,
and both, reinfection and superinfection can occur. The newly
introduced HCV genotype may either replace ("take over"), be
eliminated, or coexist with the predecessor HCV genotype. The
clinical implications of each of the these virological outcomes are
currently unclear.
Prevalence of HCV infection and risk factors for infection in
dialysis patients
Prevalence
The prevalence of anti-HCV among patients on dialysis is
consistently higher than in healthy populations, suggesting that
dialysis patients may be at higher risk of acquiring HCV infection.
Using ELISA1, the prevalence of anti-HCV among dialysis pa-
tients ranged from 8 to 36% in North America [83, 86, 113,
131—133], 39% in South America [87], 1 to 54% in Europe [89,
121, 134—1421, 17 to 51% in Asia [77, 114, 143—148] and 1.2 to
10% in New Zealand and Australia [97, 115]. The advent of
second generation tests has revealed an even higher prevalence of
anti-HCV in HD patients [77, 97, 133, 141]. Pooled data from
studies in which dialysis patients were tested by both ELISAI and
ELISA2 revealed that ELISA2 identified more than twice the
number of patients that tested positive by ELISA1 [149]. In other
studies, the prevalence of anti-HCV by ELISA2 ranged from 1.2
to 3.8 times higher than that by ELISA1, suggesting that ELISA1
underestimates the prevalence of HCV infection in dialysis units
[77—79, 97, 141, 147, 150]. At the present time, there are insuffi-
cient comparative data with the new third generation anti-HCV
tests.
In addition to the wide range in the prevalence of HCV
infection among different countries, there is also a wide variation
in the prevalence of HCV infection among dialysis units within a
single country. Among the 27,086 patients from dialysis centers
participating in the National Surveillance of Dialysis Associated
Diseases in the United States conducted by the Center for Disease
Control and Prevention (CDC), the prevalence of anti-HCV by
ELISA2 was 8.1%, with a range of 0 to 51% among centers with 
40 patients [151]. Likewise, the prevalence of HCV infection
among HD units in Portugal ranged from 0 to 75.5%, and was
lowest in the Northern regions of the country and particularly high
in the South and Central regions [152]. Also, within Saudi Arabia,
the prevalence of anti-HCV among HD units ranged from 15.4 to
94.7% [153].
Trends
The incidence and prevalence of HCV infection among patients
on dialysis is steadily declining. Among member nations in the
EDTA, the prevalence of anti-HCV declined from 21% in 1992 to
17.7% in 1993 [154, 155]. Nonetheless, the 0.4 to 15% incidence of
anti-HCV in HD units continues to be a cause for concern (Fig. 2)
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Fig. 2. Incidence of seroconversion for anti-HCV after the introduction of
screening of blood products for anti-HG V. Reference numbers are in
brackets.
[148, 156—161]. Among HD units in Portugal, the incidence of
HCV infection declined from 11.2% in 1991 to 7.2% in 1992 and
6.5% in 1993 [152]. The initial decline could be attributed to
reduction in post-transfusion HCV infection. However, as dis-
cussed later, the subsequent decline in incidence probably reflects
implementation of infection-control measures to prevent nosoco-
mial transmission within dialysis units.
The distribution of HCV genotypes among dialysis patients has
also changed significantly over the years. In France, genotype lb
accounted for more than 66% of infection prior to 1982 compared
to 50% between 1982 and 1985, and 17% after 1985 [1621. Indeed,
only genotypes la, lb and 2a were detected among dialysis and
renal transplant patients prior to 1978, whereas genotypes 3a, 4a
and 5a emerged in the 1980s [162]. The clinical significance of
these trends is currently being investigated.
Risk factors
The high incidence and prevalence of anti-HCV among patients
on dialysis can be attributed to several risk factors.
Number of blood transfusions. In numerous studies, anti-HCV-
positive HD patients had received significantly more units of
blood products than anti-HCV negative patients [71, 87, 113, 121,
139, 147, 158, 163—1661. Since the introduction of erythropoietin
and screening of blood products for anti-HCV, the risk of
acquiring post-transfusion HCV infection has declined to less
than one per 3000 units of blood products transfused [29].
Duration of ESRD. The interval since beginning dialysis was
significantly longer among anti-HCV-positive patients compared
to anti-HCV negative patients [71, 87, 121, 133, 136, 138, 147,
163—170], and the likelihood of HCV infection increases consid-
erably after a decade of HD [171]. The risk of acquiring HCV
infection on HD has been estimated at 10% per year [86]. Since a
longer time on dialysis could increase the risk of acquiring HCV
infection from blood transfusions, the question arises whether the
interval since beginning dialysis is indeed an independent risk
factor. However, stepwise regression analysis has shown that the
prevalence of anti-HCV was independently associated with both
factors, but had a stronger correlation with increasing years on
HD than with the number of blood transfusions [112, 147].
Further, in patients without a history of blood transfusion, intra-
venous drug abuse or other obvious parenteral exposure to HCV
infection, the interval since beginning dialysis correlated directly
with the prevalence of HCV infection [86, 133, 172]. These data
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suggest that time on HD is an independent risk factor for
acquiring HCV infection.
Mode of dialysis. Patients on peritoneal dialysis (PD) are at
lower risk for HCV infection, and in contrast to hemodialyzed
patients, duration of dialysis does not appear to be a risk factor for
acquiring HCV infection [145, 158, 172—177]. Data from centers
that compared the prevalence of anti-HCV in PD and HD
patients have observed a consistently lower prevalence of anti-
HCV among PD patients (Fig. 3) [160, 169, 170, 172, 173,
175—180]. In a group of 129 anti-HCV negative patients on
chronic dialysis, the rate of seroconversion was 0.15/patient-year
on HD compared to 0.03/patient-year on CAPD [181]. Further,
the majority of anti-HCV positive CAPD patients may have
acquired HCV infection while on HD. Indeed, Huang and
colleagues reported a 15.4% prevalence of anti-HCV among
peritoneal dialysis patients [177]. However, when patients with
prior HD were excluded, the prevalence decreased to 5.9% [177].
Similarly, Conway and colleagues have reported that none of the
anti-HCV positive PD patients had received PD as the sole form
of replacement therapy [139]. Several factors can account for the
lower risk of HCV infection among PD patients. (1) PD patients
have a lower requirement for blood transfusion than HD patients
[173]. (2) The absence of an access site and extracorporeal blood
circuit reduces the risk for parenteral exposure to the virus. (3)
Because PD is primarily a home procedure, it offers a more
isolated environment. Indeed, the prevalence of anti-HCV in
patients receiving home-HD is also lower than in patients receiv-
ing center-HD (Fig. 4) [122, 159, 179, 182].
Prevalence of HCJ/ infection in the dialysis unit. Patients treated
in HD units with a high prevalence of HCV infection are at
increased risk of acquiring infection [157, 183]. Indeed, a recent
survey by the Portuguese Society of Nephrology showed that the
incidence of HCV correlated directly with the prevalence of the
infection in the HD units [183]. Among units with a prevalence of
less than 19%, the annual incidence of seroconversion for anti-
HCV was 2.5% compared to a 35.3% among units with a
prevalence greater than 60%. Indeed, several investigators have
reported a relative homogeneity of HCV variants in patients
receiving treatment in the same HD [184, 185].
Other factors. A history of previous organ transplantation is a
risk factor for HCV infection in dialysis patients, possibly reflect-
ing transmission from the organ donor [176, 181]. Intravenous
drug abuse (IVDA) has been identified as an important risk factor
for HCV infection in HD patients, and a history of IVDA was
present in 30% of anti-HCV positive patients receiving HD at the
Northwest Kidney Center, Seattle and 74%, and 73% in two
urban HD units in Miami [113]. Males have been reported to have
a higher prevalence of HCV infection than females [68, 186], and
Bruguera* [182] Fig. 4. Prevalence of anti-HCV among patients
on home hemodialysis (Home HD) and in-center
hemodialysis (Center HD) in the same dialysis0% 10% 20% 30% 40% 50% 60% programs. Reference numbers are in braclets.
*First generation anti-HCV; **second
Prevalence of anti-HCV generation anti-HCV.
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DuBois and colleagues observed that male HD patients infected
with HCV had a significantly higher concentration of serum HCV
RNA than females [74]. However, there are currently no other
data available regarding gender-related differences in the natural
history of HCV infection.
Nosocomial transmission of HCV in hemodialysis units
Modes of transmission of HCV in hemodialysis units
The lower prevalence of HCV infection among PD and home
HD patients, the correlation between the interval since beginning
HD and prevalence of anti-HCV, the relationship between prev-
alence and incidence of anti-HCV in HD units, and relative
homogeneity of HCV variants in patients receiving treatment in
the same HD strongly suggest patient-to-patient transmission of
HCV in HD units. Further, several studies have implicated a
variety of potential modes of transmission.
Transmission of infection to dialysis staff by needle-stick injuty.
The prevalence of anti-HCV among dialysis staff ranges from 0 to
6% and is comparable to that in blood donors [113, 116, 117, 121,
122, 133, 147, 151, 173, 174, 177, 187—190]. In 1992, 10% of
dialysis centers in the U.S. tested staff members for anti-HCV, and
among the 2,889 staff members tested, the prevalence of anti-
HCV was 1.6% (range 0 to 6% among centers with  20 staff
members) [151]. Accidental transmission of HCV-infection from
infected patients to health care workers by needle stick injuries
has been documented [20, 191]. Indeed, genotype analysis has
been used to prove that the viral strain acquired by the medical
staff was the same as that in the index patient [18]. The risk of
transmission of HCV from infected patients to medical staff, by
needle stick injury, ranges from 2.7 to 10% [20, 192], and is
significantly lower than from HBe antigen-positive individuals
(67%) [193]. This lower risk is probably related to the low
circulating titer of HCV in humans [194], which reduces the
likelihood of HCV transmission by accidental small-volume inoc-
ulation. Chimpanzee transmission studies have shown that the
viral titer of human non-A, non-B hepatitis sera is generally less
than 102 chimpanzee-infective units [195] compared to 108 chim-
panzee-infective units for HBeAg-positive sera [196] and 1011
chimpanzee-infective units for hepatitis D virus-infected sera
[197]. Nonetheless, the need for strict adherence to general
infection-control strategies and precautions in order to protect
health care workers cannot be overemphasized.
Breakdown in standard infection control practices. The imple-
mentation of universal precautions as well as measures to reduce
the spread of HBV in dialysis units has resulted in a decline in the
incidence of NANBH in dialysis units [198]. Consequently, strict
adherence to standard infection-control practices would also be
expected to prevent the transmission of HCV. Indeed, several
outbreaks of hepatitis C in HD units have been associated with a
failure to rigidly enforce universal precautions and standard
infection-control measures, such as sharing of a multi-dose hep-
arm vial between patients with and without HCV infection and
failure to change gloves between patients while performing HD
treatments [122, 199]. In each instance, rigorous infection-control
measures, cleaning and disinfection of all instruments and envi-
ronmental surfaces that are routinely touched, and a ban on the
sharing of articles among patients resulted in a decline in the
incidence of HCV infection in the dialysis units [158, 200].
Physical proximity to an infected patient. In a multi-center study
in Belgium, 38% of the HD patients who seroconverted had never
been transfused and had no apparent risk factor for HCV
infection [157]. Interestingly, clustering of seroconversion oc-
curred only in dialysis units in which anti-HCV positive patients
were being treated. Further, a higher risk of seroconversion was
found in patients dialyzed at a station adjacent to that of an
anti-HCV positive patient as compared to other patients in the
same unit [1571. Likewise, Da Porto and colleagues have found
that anti-HCV-positive HD patients were clustered in a group of
patients who had never been transfused but who had been
dialyzed in the same section of the unit [201]. A Portuguese
Society of Nephrology survey also found the lowest incidence of
HCV infection among HD units that used isolated rooms to treat
anti-HCV positive patients [183]. These data suggest that trans-
mission of HCV may be enhanced by physical proximity.
Dialysis machines. Several reports have linked a high incidence
of HCV infection among dialysis patients who shared dialysis
machines in the HD unit [145, 169]. Further, the use of dedicated
machines and isolated areas for anti-HCV positive patients along
with strict enforcement of universal precautions was associated
with a decrease in the incidence of seroconversion [22, 200, 202].
Likewise, a survey of HD units by the Portuguese Society of
Nephrology found a significantly lower incidence of HCV infec-
tion among units that used dedicated machines for anti-HCV
positive patients [183].
Dialyzer membranes and hemodialysis ultrafiltrate. Theoretically,
the passage of HCV through intact dialyzer membranes seems
improbable as the viral particles have an estimated diameter of 35
nm, much higher than the pores of even the most permeable
dialysis membrane [203]. However, any alteration in pore size or
disruption of the membrane integrity, associated with the process
of filter assembly, the dialysis session itself, or with dialyzer re-use,
could hypothetically permit the passage of the virus into the
dialysate compartment. Two recent studies have reported that
neither low-flux (cellulose) nor high-flux (cellulose-diacetate,
polysulfone and polyacrilonitrile) dialyzers permit contamination
of the dialysis ultrafiltrate with HCV RNA [93, 204]. In contrast,
others have detected HCV RNA by PCR in the dialysate of
apparently intact polyacrilonitrile membranes, but not cellulose
membranes [205]. It is important to emphasize that detection of
HCV RNA in the dialysate by PCR may only imply the presence
of fragments of viral RNA, not the infective virus itself, a situation
which may not lead to transmission of the infection. On the other
hand, a negative PCR test does not absolutely rule out the
presence of viral RNA in the dialysis ultrafiltrate as minimal
amounts of HCV, below the detection threshold of the PCR assay,
may have passed through the dialysis membrane, However, such a
low viral load in the dialysis ultrafiltrate may represent only a
negligible risk of transmission of HCV infection. To date, a higher
prevalence of anti-HCV among HD patient has not been associ-
ated with any particular dialysis membrane [87, 122, 148, 152,
157].
Reprocessing of dialyzers. In a prospective study in 15 I-ID units
in Belgium, Jadoul and colleagues did not find a higher incidence
of HCV infection among patients treated in units that reprocessed
dialyzers compared to those that did not [157]. Likewise, a
Portuguese Society of Nephrology survey also found that the
incidence of HCV infection among patients in HD units that
reprocessed dialyzers was not significantly different than in units
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that did not reprocess dialyzers [1831. However, among units that
did reprocess dialyzers, the lowest incidence was observed among
patients in units that used separate rooms to reprocess dialyzers
from anti-HCV positive and anti-HCV negative patients or had a
ban on reprocessing dialyzers from anti-HCV positive patients.
These data suggest that contamination in the reprocessing room
may be a vector for the transmission of HCV in HD units.
Strategies to control the transmission of HCV infection in
hemodialysis units
The high prevalence of HCV infection among patients on HD,
the limitations of current tests in identifying these patients and
uncertainty regarding the modes of transmission within dialysis
units have led to difficulty in formulating policies regarding HCV
infection in HD units. The debate on the need for routine testing
for anti-HCV, and efficacy of patient isolation, dedicated ma-
chines and ban on reuse of dialyzers in controlling transmission of
HCV infection in HD units has not been resolved. Arguments in
favor of such strategies in HD units include: (1) HCV is paren-
terally transmitted, and HD patients are at risk of nosocomial
transmission; (2) Other parenterally transmitted viruses such as
HBV have been shown to be transmitted within HD units; and (3)
Similar strategies to reduce the transmission of FIBV have re-
sulted in a decrease in the incidence of HBV infection in HD units
[206].
However, there are strong arguments against a policy of
isolating anti-HCV positive patients and their machines because:
(1) HCV is not as infective as HBV, circulates in low titers in
infected serum and is rapidly degraded at room temperature [194,
207]; and (2) Currently licenced anti-HCV tests detect non-
neutralizing antibodies, do not distinguish between current and
past infection, and a negative test does not exclude HCV infec-
tion. Consequently, isolation of anti-HCV positive patients does
not eliminate the risk of transmission. Although the previous
problem could potentially be circumvented by testing for HCV
RNA by PCR, this test is not licenced for clinical use, is expensive,
requires a specialized laboratory, and technical limitations can
lead to false positive and false negative results; and (3) Although
isolation may protect uninfected patients, it might also increase
the risk of superinfection in patients originally infected with a
single strain [60]. Indeed, infection with two or more different
HCV genotypes has been observed in HD patients and 13% of
patients referred for renal transplantation [18, 208]. The clinical
impact of such poly-genotype infections are currently undefined.
In view of the above debate, the Centers for Disease Control
and Prevention in the U.S. (CDC) does not recommend dedicated
machines, patient isolation or a ban on re-use in HD patients with
HCV infection [198]. Meanwhile, strict adherence to "universal
precautions," careful attention to hygiene and strict sterilization
of dialysis machines is recommended [72, 122, 157]. Conventional
cleansing and sterilization appear to be adequate to inactivate the
virus [122, 1571. Unfortunately, eliminating the spread of HCV
infection in HD units may require the development of treatments
to eradicate the virus or vaccines to prevent infection.
Transmission of HCV by organ transplantation
Transmission of HCV infection
Shortly after the introduction of the first generation anti-HCV
tests, the New England Organ Bank initiated studies to evaluate
the risk of transmission of HCV infection by anti-HCV positive
cadaver organ donors. Stored sera from 716 consecutive cadaver
organ donors between 1986 and 1990 (prior to the availability of
anti-HCV tests) were screened for anti-HCV using the ELISAI,
and 13 (1.8%) anti-HCV positive donors were identified [81, 209].
Of the 29 recipients of organs from these anti-HCV positive
donors, fourteen (48%) developed post-transplantation non-A,
non-B hepatitis within a mean follow-up interval of 20 months, a
prevalence that was seven- to eightfold higher than that among
recipients of untested donors in previous studies [2, 4]. Further, of
the 14 recipients who developed NANBH, two (14%) died from
sub-fulminant liver failure and 12 (86%) developed chronic liver
disease. Liver pathology was available in eight patients and
revealed chronic active hepatitis in six patients and cirrhosis in
two patients. Among the 24 recipients in whom post-transplanta-
tion sera were available, 16 (67%) tested positive for anti-HCV,
and 23 (96%) tested positive for HCV RNA by PCR. All thirteen
HCV RNA negative recipients of organs from HCV RNA positive
donors tested positive for HCV RNA after transplantation. These
observations unequivocally demonstrated the transmission of
HCV by organ transplantation. Similar studies have been under-
taken by other organ procurement organizations and transplant
centers (Table 2). Overall, among recipients of organs from
anti-HCV positive donors, 35% (range 0 to 55%) developed
post-transplant liver disease, 50% (range 14 to 100%) tested
positive for anti-HCV after transplantation, and 74% (range 57%
to 96%) tested positive for HCV RNA by PCR [81, 118, 209—221].
The differences in the rate of transmission of HCV infection by
anti-HCV positive donors reported by different centers could be
due to several factors. First, clinical or laboratory evidence of liver
disease, and testing for anti-HCV among organ transplant recip-
ients significantly underestimates the prevalence and transmission
of HCV infection [81]. Hence, failure to test recipients for HCV
RNA at some centers could erroneously suggest a low rate of
transmission of HCV infection. Second, the risk of transmission of
HCV infection by anti-HCV positive cadaver organ donors could
be related to the prevalence of HCV RNA among these donors
[2221. A lower prevalence of HCV RNA among anti-HCV
positive cadaver organ donors at some centers could explain the
lower rate of transmission of HCV by anti-HCV positive donors
reported by these centers [211, 223, 224]. Finally, some authors
have suggested that reduction of the viral inoculum by pulsatile
perfusion of the organs as opposed to cold storage could reduce
the transmission of HCV by infected organs [211]. This possibility
however, remains to be proven.
Clinical impact of transmission of HCV infection
Long-term studies from the New England Organ Bank have
compared post-transplantation clinical outcomes in the 29 recip-
ients of organs from the 13 anti-HCV positive cadaver organ
donors [81] to 74 recipients from 37 randomly selected anti-HCV
negative donors [2101. After a median follow-up of 42 and 49
months, respectively, the relative risk of liver disease was in-
creased fourfold among recipients from anti-HCV positive do-
nors, and four (14%) of the 29 patients died due to or with liver
failure. However, there was no increase in graft loss (relative risk
0.93, 95% confidence intervals of 0.51 to 1.70) or death (relative
risk 0.89, 95% confidence intervals of 0.41 to 1.93) among
recipients from anti-HCV positive donors. Mendez and col-
leagues prospectively studied 42 anti-HCV negative recipients of
Recipient 2b, Donor 3a
Recipient 2b, Donor 3a
Recipient lb. Donor la
t
Recipient 3a, Donor la
I L*#
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Table 2. Transmission of HCV infection by anti-HCV positive cadaver organ donors
Fig. 5. HCV genotype(s) detected in the serum of
HCV RNA positive recipients of kidneys from
HCV RNA positive donors at the time of0 3 6 9 12 15 18 21 24 27 transplantation and at different time intervals after
transplantation (226]. Symbols are: (U)
Months post-transplantation recipient; (•) both; (U) donor.
kidneys from anti-HCV positive donors [225]. After four years of
follow-up, the prevalence of liver disease was higher than controls,
but patient survival was not significantly different. Pirsch and
colleagues prospectively transplanted 69 kidneys from anti-HCV
positive donors in anti-HCV negative recipients who were consid-
ered to have a limited life expectancy [220]. After a short
follow-up, one patient died of fulminant hepatitis and two patients
developed cirrhosis [220]. Survival among recipients from anti-
HCV positive donors was significantly lower compared to recipi-
ents from anti-HCV negative donors [2201. Overall, these data
indicate a higher risk of liver disease, but no significant adverse
effect on patient or graft survival. However, it is noteworthy that
sub-fulminant hepatitis was reported only among patients who
received organs from anti-HCV positive donors.
Transplantation of kidneys from anti-HCV positive donors into
recipients with pre-transpiantation HCV infection
In chimpanzees, previous infection with HCV does not protect
from reinfection with a different strain or even the same strain of
the virus [60]. Likewise, dialysis and transplant patients with
pre-existing HCV infection are not protected from superinfection
with a new HCV genotype [226, 2271. Indeed, two recent reports
have demonstrated that among HCV RNA positive recipients of
kidneys from HCV RNA positive donors, the viral genotype
present post-transplantation was either the same genotype
present pre-transpiantation, the genotype from the donor or both
(Fig. 5) [226, 227]. The clinical implications of superinfection in
transplant recipients is not well defined, in a prospective study
from Spain, there were no differences in the post-transplantation
prevalence of liver disease, graft or patient survival between 24
anti-HCV positive recipients who received kidneys from anti-
HCV positive donors compared to 40 anti-HCV positive recipi-
ents of kidneys from anti-HCV negative donors [228]. However,
four (80%) of five anti-HCV positive but PCR negative recipients
from PCR positive donors acquired HCV RNA [228]. These data
suggest that superinfections do occur, but may they not have
serious clinical consequences, at least in the short-term, The
safety of transplanting organs from anti-HCV positive donors in
Author Study
Post-transplant recipient characteristics
Liver disease Anti-HCV HCV RNA
Country [Reference] period N % N % N %
USA Pereira [81, 209] 1986—90 16/29 55 16/24 67 23/24 96
USA Roth [2111 1979-91 13/46 28 10/31 32 NA NA
Taiwan Huang [2121 1985—91 7/19 37 14/19 74 18/19 95
USA Vincenti [2131 1990 0/7 0 1/7 14 1/7 14
Spain Gomez [214] 1990 2/4 50 2/4 50 NA NA
Italy Triolo [215] 1984—90 2/13 15 13/13 100 NA NA
USA LeFor [216] 12/30 40 NA NA NA NA
USA Aeder [118] 1988—90 5/25 20 11/24 46 13/22 59
USA Tesi [2171 1990—93 18/43 42 15/43 35 21/37 57
UK Wreghtt [218] 1984—91 7/15 47 6/15 40 12/14 86
Spain Prados [219] 1992 2/6 33 5/6 83 5/6 83
USA Pirsch [220] 1991—94 NA NA NA NA 47/61 77
84/237 35 93/186 50 140/190 74
NA is not available.
Recipient 2b, Donor 3a
#01
 
#02
C
. #03
,
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Table 3. Prevalence of markers of HCV infection among organ donors
Organ procurement organization Country
Author
[Reference]
Study
period
Donors
tested
ELISA1 ELISA2 PCR
%
U.S. National Collaborative Study USA Pereira [222] 1986—92 3078 5.10 4.2 2.4
New England Organ Bank, Massachusetts 1986—92 1012 2.90 2.4 1.7
Regional Organ Bank of Illinois, Illinois 1987—91 596 6.00 3.2 2.7
Lifelink Inc., Florida 1985—91 521 7.70 7.3 4.0
Center for Organ Recovery and Education, Philadelphia 1986—90 516 5.80 5.4 2.1
Midwest Organ Bank, Kansas 1988—90 172 4.70 4.1 2.0
Louisiana Organ Procurement Agency, Louisiana 1990—91 129 2.30 2.3 0.8
Oregon Health Sciences University, Oregon 1990—91 67 1.50 NA NA
Washington Hospital Center, Washington, D.C. 1991 66 16.70 8.3 4.2
California Transplant Donor Network, California USA Vincenti [213] 1989—90 205 5.90 NA NA
University of Miami, Florida USA Roth [2111 1979—91 484 18.00 6.8 3.4
National Organization of Transplantation Spain Miranda [230] 1992 360 NA 1.6 NA
Chang Gung Memorial Hospital, Taipei Taiwan Huang [212] 1985—91 110 NA 11.8 11.8
S. Giovanni-Molinette Hospital, Turin Italy Triolo [215] 1984—90 241 NA 4.0 NA
Addenbrooke's Hospital, Cambridge UK Wreghtt [218] 1984—91 554 NA 1.08 NA
Hospital Alacant, Alicante Spain Prados [219] 1992 77 NA 3.89 3.89
Hospital Covadonga, Oviedo Spain Gomez [2141 1985—90 78 3.80 NA NA
NA is not available.
recipients with pre-transplantation HCV infection could possibly
be further enhanced by testing patients on the waiting list for
HCV RNA by PCR and identifying the genotypes present. These
patients could potentially receive an organ from a donor matched
for the HCV genotype. The development of type-specific antibody
tests that could rapidly identify the donor HCV genotype are a
major step in making such transplants a reality [1231.
Policies concerning the use of organs from donors with HCV
infection
Based on the high prevalence of HCV infection among recipi-
ents of organs from anti-HCV positive donors, several organ
procurement organizations (OPOs) adopted a policy of testing all
cadaver organ donors for anti-HCV and restricting the use of
organs from anti-HCV positive donors to life-saving transplants
(heart, liver or lung) [118, 2091. Similar policies were recom-
mended by the U.S. Public Health Service Inter-Agency guide-
lines [229]. However, because of the wide range in the prevalence
of liver disease and HCV infection after transplantation of organs
from anti-HCV positive donors and the absence of a definitive
evidence of a detrimental effect on patient survival, a complete
moratorium on transplantation of organs from anti-HCV positive
donors may not be appropriate [225, 228]. The discussion in this
section will compare the impact of potential strategies on organ
procurement and transmission of infection.
Prevalence of HCV infection among cadaver organ donors and
performance of anti-HG V tests. The prevalence of HCV infection
among cadaver organ donors varies worldwide (Table 3) [21]—
215, 218, 219, 222, 230]. In 1992, we initiated a national collabo-
rative study by eight OPOs representing different geographical
regions of the U.S. [222]. Among 3078 cadaver organ donors, the
prevalence of a positive ELISA1 was 5.1% with a range from 1.5%
to 16.7% (Table 3). Sera from these ELISA1 positive donors and
100 randomly selected ELISAI negative cadaver organ donors
were retrieved for testing by ELISA2 and PCR. The extrapolated
prevalence of ELISA2 and HCV RNA among cadaver organ
donors was 4.2% and 2.4%, respectively. Based on these data, we
computed the sensitivity and specificity of the ELISA2 assay in
detecting HCV infection to be 100% and 98.1%, respectively.
Consequently, in this population the positive and negative predic-
tive values of the ELISA2 assay were 55.1% and 100%, respec-
tively. Based on these estimates, discarding organs from ELISA2
positive donors would eliminate transmission of infection, but
4.2% of donors would be discarded and kidneys from 1.88% of
donors (anti-HCV positive, HCV RNA negative) would be
wasted.
Some investigators had suggested that social, demographic and
clinical data could be used to predict which anti-HCV positive
donors have HCV RNA [223, 224]. Specifically, it had been
suggested that anti-HCV positive donors with no history of drug
abuse or homosexual lifestyle, absence of anti-HBs or anti-HBc,
and normal serum alanine aminotransferase levels were at lower
risk of transmitting disease and could hence be used for trans-
plantation [223, 224]. However, in the national collaborative
study, we found that these characteristics did not distinguish
anti-HCV positive donors with and without serum HCV RNA
[222]. Thus, we concluded that there are no "low-risk" anti-HCV
positive cadaver organ donors defined by clinical criteria. Another
strategy to improve the prediction would be to develop corifirma-
tory tests for use in donors with a positive ELISA2. However, in
our study, the RIBA2, which has been suggested as a confirmatory
test in blood donors, was not specific enough to distinguish
ELISA2 positive organ donors with and without serum HCV
RNA. Hence, newer confirmatory tests with an even greater
specificity need to be developed in order to improve the predic-
tion of HCV RNA among cadaver donors.
Impact of policies concerning the use of kidneys from donors with
HGV infection. With the current shortage of cadaver kidneys and
the waiting list constantly growing, it is important to carefully
consider the impact of different policies concerning the use of
organs from anti-HCV positive cadaver organ donors. We calcu-
lated the impact of these policies on organ discard, transmission
of HCV, and acquisition of new infection after transplantation
(Table 4). For this discussion, we will restrict our consideration to
policies regarding kidney donation because more data are avail-
able regarding HCV infection in kidney donors and recipients
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Table 4. Implications of policies concerning the use of kidneys from
ant i-HCV positive cadaver organ donors [231]
Policy Organ loss Transmission New infection
No restriction 0% 2.4% 2.0%
Complete restriction 4.2% 0% 0%
Restricted to anti-HCV 0% 2.4% 0.5%
positive recipients
Restricted to HCV RNA 0% 2.4% 0%
positive recipients
Pereira, Pediatric Nephrology, 1995, by permission of Oxford University
Press.
[231]. Our estimates are based on the following assumptions: (1)
Procurement of 8161 kidneys were recovered from 4843 cadaver
organ donors (1.7 kidneys per donor) in the U.S. in 1993 [2321; (2)
31,115 patients on the waiting list for kidney transplantation
during that same year; (3) a 2.4% prevalence of HCV infection
among cadaver organ donors [222]; (4) a 100% sensitivity and
98.1% specificity of ELISA2 in detecting donors with HCV
infection [222]; (5) a 100% transmission of HCV infection by
HCV RNA positive donors [81, 222]; (6) a 20% prevalence of
anti-HCV in dialysis patients and an 80% prevalence of HCV
RNA among anti-HCV positive patients (indicating current infec-
tion) [228]; and (7) no apparent clinical consequence of superin-
fection [228]. We used the following definitions: (1) organ discard
is the loss of organs from otherwise suitable cadaver donors
because of a positive test for anti-HCV; (2) transmission of
infection is transmission of HCV RNA from donor to recipient;
and (3) new infection is acquisition of HCV RNA from the donor
by a recipient who did not have HCV RNA at the time of
transplantation.
Based on the above assumptions, no restrictions on the use of
organs from anti-HCV positive donors ("no restriction," Table 4,
line 1) would lead to no loss of organs, but transmission of
infection to 2.4% of recipients (196 recipients) and new infection
in 2.0% of uninfected recipients (165 recipients). In our view, the
higher prevalence of liver disease and potential long-term mor-
bidity and mortality among these recipients makes such a policy
undesirable. Nonetheless, we recognize patients' autonomy to
make decisions when data on morbidity and mortality are not
conclusive. On the contrary, a nationwide moratorium on the use
of kidneys from anti-HCV positive donors ("complete restric-
tion," Table 4, line 2) would eliminate transmission of infection,
but result in the discard of kidneys from 4.2% of cadaver organ
donors (346 kidneys). At a time of severe shortage of cadaver
organs, the loss of 346 otherwise suitable kidneys is also undesir-
able. If use of organs from anti-HCV positive donors were
restricted to recipients with pre-transplant anti-HCV (Table 4,
line 3), no organs would be discarded, HCV infection would be
transmitted to 2.4% of recipients (196 recipients), but new
infection would occur in only 0.5% (41 recipients). If instead,
organs from anti-HCV positive donors were restricted to recipi-
ents with pre-transplant HCV RNA (Table 4, line 4), transmission
of HCV infection to previously uninfected recipients would be
eliminated, but this strategy would require pre-transplant testing
of potential recipients for HCV RNA by PCR. Moreover, if it
were possible to test anti-HCV positive donors by PCR and
genotype match PCR positive donors and recipients, superinfec-
tion with a different strain could also be eliminated. At the current
time, there is not sufficient data to fully evaluate these latter two
strategies. In our view, short-term clinical data on outcomes
among anti-HCV positive recipients of kidneys from anti-HCV
positive donors justify further study of these latter two strategies.
HCV infection in renal transplant recipients
Effect of pre-transplantation anti -HC V status on post-
transplantation clinical outcomes
Among renal transplant recipients, the prevalence of pre-
transplantation anti-HCV is 11 to 49% [167, 233—239]. Pre-
transplantation anti-HCV is associated with an increased risk of
post-transplant liver disease and is reported in 19 to 64% of
recipients compared to 2 to 19% among recipients without
anti-HCV (Table 5) [233, 234, 236, 238, 239]. Indeed, studies from
the New England Organ Bank have shown that for recipients with
anti-HCV prior to transplantation, the relative risk of post-
transplantation liver disease was 5.0 (95% confidence intervals of
2.4 to 10.5) [233]. Among patients with pre-transpiantation HCV
RNA in the serum, kidney transplantation was associated with a
1.8- to 30.3-fold increase in viral titer, suggesting that kidney
transplantation is associated with proliferation of the hepatitis C
virus. However, among patients with HCV RNA detected in the
serum, the titer of HCV RNA did not differ between patients with
and without post-transplantation liver disease. These data suggest
that factors other than the viral load determine the risk of liver
disease among transplant recipients with HCV infection.
Although pre-transpiantation anti-HCV is consistently associ-
ated with an increased risk of post-transplantation liver disease,
post-transplantation patient survival was adversely affected in only
some studies (Table 5). Studies from the Roth and colleagues at
the University of Miami [236], Ynares and colleagues at Vander-
bilt University [238], and Stempel and colleagues at the University
of California at San Francisco [234] failed to detect significant
differences in patient survival between recipients with and without
anti-HCV prior to renal transplantation (Table 5). In contrast,
studies from Fritsche and colleagues at the Medical College of
Wisconsin [239] reported a lower eight-year patient survival
among the anti-HCV positive recipients compared to anti-HCV
negative controls. Likewise, our results from the New England
Organ Bank study revealed that recipients with pre-transplanta-
tion anti-HCV had a 3.3-fold higher risk of death (95% confi-
dence intervals of 1.4 to 7.9) and a 9.9-fold higher risk of death
due to sepsis (95% confidence intervals of 2.6 to 38.3) [233].
Interestingly, infection rather than liver failure was the leading
cause of death among anti-HCV positive recipients. The differ-
ences among studies in patient survival could be due to several
factors, such as: (1) differences in study design such as selection of
patients, and length and completeness of follow-up; (2) virus and
test factors such as sensitivity and specificity of anti-HCV test,
prevalence of serum HCV RNA, genotype of infecting virus and
single or mixed infection; and (3) the presence and severity of
pre-transplant liver disease, HLA matching and immunosuppres-
sion protocols. Indeed, the severity of pre-transplant liver disease
has been shown to be an important predictor of adverse post-
transplant outcomes [Ii].
Effect of renal transplantation on the course of HCV infection in
dialysis patients
Although some studies have shown that anti-HCV at the time
of renal transplantation is associated with an increased risk of
death, it is not known whether survival for anti-HCV positive
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Table 5. Impact of pre-transpiantation anti-HCV on post-transplantation clinical outcomes
Author
[Referencel Study period Anti-HCV N
Post-transplantation
Liver
disease
Actuarial
graft survival
years
Actuarial
patient
survival years
Pereira [233]
Roth [236]
Ynares [238]
1986—90
1979—91
1980—81, 86—87
ELISA2 positive
ELISA2 negative
RIBA2 positive
RIBA2 negative
ELISA1 positive
ELISAI negative
23
80
109
200
65
195
64%
19%
34%
19%
29%
7%
50%
59%
81% (5)
80% (5)
33% (it))
25% (10)
59%U
85%°
63% (5)
63% (5)
53% (10)
54% (10)
Fritsche [239] 1979—90 ELISA2 positive
ELISA2 negative
53
256
19%
2%
32% (10)
53% (10)
58% (8)
82% (8)
a As of 12/93; for actuarial graft and patient survival, the numbers in parenthesis indicate duration (years)
patients is greater with treatment by dialysis or transplantation.
For several reasons, it has been assumed that transplantation and
immunosuppression increases the risk of liver disease and death
among anti-HCV positive dialysis patients. (1) HBsAg positive
patients who undergo renal transplantation have a higher mor-
bidity and mortality than patients who continued on dialysis [51.
(2) Liver disease is seen more often among anti-HCV positive
transplant recipients who receive anti-lymphocyte preparations
such as antilymphocyte globulin, anti-thymocyte globulin or
OKT3 [209, 240]. (3) Among patients with HJV infection, the
acquired immunodeficiency syndrome develops 1.5 to 2 years
after infection in immunosuppressed transplant recipients, com-
pared to seven to eight years in normal hosts [241]. However, the
prevalence of liver disease among anti-HCV positive transplant
recipients (19 to 66%) does not appear to exceed the prevalence
among anti-HCV positive dialysis patients (18 to 80%) [83, 113,
136, 167, 178, 242—2481. Preliminary results from a New England
Organ Bank Study comparing survival between anti-HCV positive
patients who underwent renal transplantation and anti-HCV
positive patients referred for transplantation but who remained
on dialysis do not suggest that renal transplantation adversely
affected survival [249]. Among anti-HCV positive patients await-
ing transplantation between 1986 and 1990, the relative risk of
death among those who received a transplant was 0.94 (95%
confidence intervals, 0.55 to 1.59) compared to those who did not
undergo transplantation. However, the wide confidence interval
precludes definitive conclusions. In the absence of definite studies
demonstrating worse outcomes after renal transplantation, we
suggest that anti-HCV positive patients without evidence of liver
disease should be allowed to make an informed choice of staying
on dialysis or undergoing transplantation. However, as discussed
earlier, patients on dialysis and transplant recipients can have
histological evidence of liver disease in the absence of elevated
serum ALT levels. Because the histological severity of liver
damage is a strong predictor of liver failure and death after
transplantation, there may be merit in a policy to perform liver
biopsies on anti-HCV positive patients awaiting renal transplan-
tation. In patients with histological evidence of liver disease, the
decision to proceed with renal transplantation should be made
cautiously, after taking into consideration the influence of immu-
nosuppression on viral replication and possible exacerbation of
liver disease.
Role of interferon alpha in the treatment of chronic hepatitis C
infection in patients with ESRD
Treatment of acute HCV infection is not generally recom-
mended in non-immunosuppressed patients. However, interferon
alpha (IFNcs) has been used with a fair degree of success in
patients with histological evidence of chronic hepatitis due to
HBV, HCV and hepatitis D infection [250—257]. The dose
requirement and response to treatment differ among the three
types of viral hepatitis. By the end of therapy (4 months in
hepatitis B and D, and 6 months in hepatitis C), complete
normalization of elevated liver enzymes and clearance of virus
from the serum is observed in 30 to 40% of patients with chronic
hepatitis D and 50% of patients with chronic hepatitis B or C
[250—255]. The dose required to induce remission in chronic
hepatitis C (3 million units administered 3 times a week) is
threefold lower than that used in chronic hepatitis B or D (9 to 10
million units administered 3 times a week). Remission is sustained
in the majority of patients with chronic hepatitis B who demon-
strate a response to interferon treatment [253, 254]. In contrast, a
sustained response to interferon treatment is observed in only 20
to 25% of patients with chronic hepatitis C or D. The efficacy of
longer period of treatment and higher doses are currently being
evaluated [2571.
Among patients with chronic hepatitis C, the pre-treatment
clinical, biochemical, histological and viral characteristics that
predict the success of interferon treatment have been the subject
of intense investigation. Patients with lower levels of viral RNA in
the serum, and lower concentration of HCV antigens in the liver
are more likely to respond to interferon treatment [258]. Prelim-
inary results of a large European multi-center study suggest that
age under 40 years, absence of cirrhosis, pre-treatment ALT levels
less than three times the upper limit of normal, post-transfusion
rather than sporadic infection and infection with the genotypes 1,
5 and 6, are predictors of response to interferon treatment [259].
However, others have shown that patients infected with genotypes
2 and 3 have a better response to interferon than those infected
with genotype 1 [2601. Some of the differences in the relationship
between HCV subtypes and response to interferon treatment
could be related to the lack of uniformity in the viral nomencla-
ture followed by different groups, and the different types of
interferon used. Nevertheless, tailoring interferon treatment
based on viral types promises to be an exciting possibility.
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Table 6. Initial response to interferon alpha treatment in dialysis and transplant patients with chronic hepatitis C
Author
[Reference]
Study
population N
Decrease in
serum ALT
Improvement
in liver
histologya
Clearing of
serum HCV
RNA
Rao [2631 HD + Tx 10 100% 80% NA
Pol [264] HD 19 85% NA 53%
Rostaing [2651 Tx 16 100% NA 0%
Casanovas [266] HD 10 90% NA 10%
Koenig [267] HD 37 71% NA 65%
Duarte [268] HD 5 100% NA NA
Harihara [2691 Tx 3 67% NA NA
Raptopoulou [270] HD 19 100% NA 77%
Ozgur [271] Tx 5 100% 100% NA
Abbreviations are: HD, hemodialysis patients; Tx, transplant recipients.
Among patients who had an abnormal test prior to treatment and who completed the course of treatment
IFNcr has pleiotropic effects including anti-proliferative and
immunomodulatory properties as well as anti-viral activity [256].
Indeed, IFNcs induces cytokine gene expression, increased cell
surface expression of HLA antigens and enhanced function of
natural killer cells, cytotoxic T cells and monocytes. Further, the
use of IFNa as prophylaxis against CMV disease in renal trans-
plant recipients has been associated with a high incidence of
steroid-resistant allograft rejection resulting in graft loss [261,
262]. Since IFNa treatment carries a risk of inducing or facilitat-
ing rejection in allograft recipients, questions have been raised
regarding the efficacy, tolerance, safety and timing of IFNcs
therapy in dialysis and transplant patients.
As shown in Table 6, the initial response of dialysis and
transplant patients to IFNa treatment has been encouraging with
a majority of patients demonstrating a decrease in serum ALT
levels and an improvement in liver histology [263—271]. However,
as in the case with non-renal patients, relapses are common after
stopping treatment and long-term outcomes are not yet ade-
quately defined [264, 265]. Further, although disappearance of
HCV RNA from the serum is common, recurrence of viremia
from extra-vascular sites remains a distinct possibility [82, 265].
A major stumbling block to IFNcs treatment in transplant
recipients has been the occurrence of acute rejection. A majority
of studies have observed an increased risk of acute rejection (40%
to 100%) among transplant recipients treated with IFNa for
chronic liver disease due to hepatitis C [265, 269, 271, 272]. In
contrast, Rao and Anderson did not encounter allograft rejection
in six renal transplant recipients treated with IFNx two to 15 years
after transplantation [263]. The absence of rejection in the study
by Rao and Anderson could be attributed to the fact that the
patients had stable renal function for several years prior to the
start of IFNa therapy and were hence at low risk of rejection.
However, others have demonstrated irreversible rejection and
return to dialysis in patients treated with IFNa as late as eight
years after transplantation [269, 2711. Similarly, patients treated
with IFNa to prevent post-transplantation CMV or EBV infection
also experienced an increased incidence of acute rejection.
Treatment with IFNa is also associated with a "flu-like" syn-
drome with asthenia, myalgia, headache and, neutropenia, throm-
bocytopenia and depression, and is partly related to the dose
administered [273]. Despite these side effects, the drop-out rate
among non-renal patients treated with IFNcr has been surprisingly
low [273]. In contrast, treatment was stopped for reasons other
than transplant rejection in 0 to 54% of dialysis and transplant
recipients treated with IFNa [263—267]. The reasons for this
difference between non-renal and renal patients is currently
unclear.
Overall, the limited efficacy of IFNa, together with its high cost,
risk of acute rejection and side-effects have diminished enthusi-
asm for its use in transplant recipients with chronic HCV infec-
tion. A safer, but probably less cost-effective strategy might be to
treat dialysis patients with chronic hepatitis C prior to transplan-
tation. Indeed, two recent studies in patients with chronic hepa-
titis C who were treated with IFNa while on dialysis did not
observe recurrence of liver disease or an increased risk of
rejection after subsequent transplantation [266, 268]. Controlled
studies will be required to evaluate the long-term effects of this
strategy on the course of liver disease, rates of transplantation,
graft and patient survival.
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